Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM
| Conditions: | Mesothelioma |
| Start Date: | October 1, 2007 |
| Phase: | Phase I|Phase II |
| Status: | Active, not recruiting |
| NCT ID: | NCT00604461 |
| Study Type: | Interventional |
| Intervention: | Drug: Carboplatin, Bevacizumab and Pemetrexed |
| Study Design: | Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | H. Lee Moffitt Cancer Center and Research Institute|Genentech |
| Ages: | Adult|Senior |
| Enrollment: | 48 |
| Funded By: | Other|Industry |
| First Received: | January 17, 2008 |
| End Date: | January 1, 2011 |
| Last Updated: | February 11, 2010 |
| Last Verified: | February 1, 2010 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
